Descripción del proyecto
Modulación del sistema inmunitario tras un infarto de miocardio
Las estrategias de tratamiento actuales para la cardiopatía isquémica solo mejoran los síntomas. El proyecto financiado con fondos europeos MiNeMI está trabajando en un método inmunomodulador novedoso que pretende regular la inflamación y respaldar la regeneración tras un infarto de miocardio. Sus investigadores están desarrollando un parche cutáneo no invasivo basado en microagujas cargado con moléculas biológicas e inmunomoduladoras. La idea es liberar estos tratamientos en la capa dérmica de la piel, donde se encuentra un reservorio de células inmunitarias. La eficacia y seguridad del método de MiNeMI será probado «in vitro» y en un modelo animal de cardiopatía isquémica.
Objetivo
Cardiovascular diseases are the leading global cause of death, being ischemic heart disease one of the deadliest. To date, the conventional therapeutics only ameliorate the state of care of myocardial infarction (MI) patients, and no approved therapy has been developed for heart scars. Promising approaches might come based on the latest knowledge on new pathophysiological concepts, e.g. on the inflammation and immune responses upon MI. The inflammatory phase on MI presents itself as a therapeutic opportunity, with immunomodulation for heart regeneration showing great promise for MI treatment.
Thereby, MiNeMI aims to answer the question if it is possible to modulate the immune system to regulate inflammation and promote heart regeneration through a non-invasive approach. To this end, MiNeMI will, for the first time, develop a novel and unique double-layer biodegradable non-invasive microneedle (MN)-assisted nanovector skin patch, loaded with both immunomodulatory and biologic (cytokines, proteins, and extracellular vesicles) cargos to be tested in a myocardial infarction (MI) disease model. The MN-patch approach proposed here will deliver the cargos into the dermal layer of the skin, a reservoir of immune cells, and will revolutionize the way to regulate the inflammatory systemic immune response upon cardiac ischemia. This MN-assisted nanovector skin patch will be fully characterized in vitro for immune and cardiac effects and also tested in animal MI disease models.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinador
00014 Helsingin Yliopisto
Finlandia